drugset / Trial / NCT00771979
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
RandomizedCrossoverOpen-labelBasic science
Summary
The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.
Timeline
- Start
- 2008-11
- Primary completion
- —
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | saracatinib | Small molecule | 125 mg | Oral |
Indications
No indication recorded.